Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Calreticulin is a multifunctional, calcium-binding chaperone protein primarily located in the endoplasmic reticulum (ER). Mutations in the calreticulin gene (CALR) are most notably associated with certain myeloproliferative neoplasms (MPNs), where they drive disease pathogenesis through altered molecular interactions and signaling pathways. The most common mutations are insertions or deletions (INDELs) in exon 9 of CALR, resulting in a +1 frameshift that alters the C-terminal sequence and the loss of the KDEL ER-retention signal. Mutant calreticulin acquires a novel ability to bind directly to MPL (the thrombopoietin receptor), activating it independently of its ligand, which drives uncontrolled cell proliferation via JAK-STAT signaling.
Targeting mutant CALR neoepitopes with cancer vaccines; Inhibition of the MPL-JAK2 pathway
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Calreticulin Mutant Protein (CALR mutant).